ZK-283197
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
Other names | BAY 86-5310; SH-T04211C |
Routes of administration | By mouth[1] |
Drug class | Estrogen; Selective ERβ agonist |
Identifiers | |
CAS Number |
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]
References[]
- ^ a b c d "ZK 283197 - AdisInsight". adisinsight.springer.com.
- ^ US 332204, Pietras, R. J., & Jung, M. E., "Methods of using estrogen receptor-beta ligands as radiation mitigators", published 2015-01-15
![]() | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by . |
- v
- t
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Abandoned drugs
- Drugs with undisclosed chemical structures
- Selective ERβ agonists
- Synthetic estrogens
- Genito-urinary system drug stubs
- Nervous system drug stubs
Hidden categories:
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles